442 related articles for article (PubMed ID: 18572972)
1. Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma.
Kopp HG; Patel S; Brücher B; Hartmann JT
Am J Clin Dermatol; 2008; 9(4):207-17. PubMed ID: 18572972
[TBL] [Abstract][Full Text] [Related]
2. Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
Hartmann JT
Anticancer Drugs; 2007 Mar; 18(3):245-54. PubMed ID: 17264755
[TBL] [Abstract][Full Text] [Related]
3. Emerging therapies for adult soft tissue sarcoma.
Radaelli S; Stacchiotti S; Casali PG; Gronchi A
Expert Rev Anticancer Ther; 2014 Jun; 14(6):689-704. PubMed ID: 24555529
[TBL] [Abstract][Full Text] [Related]
4. New therapeutic strategies for soft tissue sarcomas.
von Mehren M
Curr Treat Options Oncol; 2003 Dec; 4(6):441-51. PubMed ID: 14585225
[TBL] [Abstract][Full Text] [Related]
5. Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma.
Hartmann JT; Patel S
Drugs; 2005; 65(2):167-78. PubMed ID: 15631540
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
7. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
Karavasilis V; Seddon BM; Ashley S; Al-Muderis O; Fisher C; Judson I
Cancer; 2008 Apr; 112(7):1585-91. PubMed ID: 18278813
[TBL] [Abstract][Full Text] [Related]
8. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
9. [Systemic therapy of soft tissue sarcomas].
Pink D; Bertz-Lepel J; Reichardt P
Pathologe; 2011 Feb; 32(1):65-71. PubMed ID: 21053001
[TBL] [Abstract][Full Text] [Related]
10. Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine.
Reed D; Altiok S
Cancer Control; 2011 Jul; 18(3):188-95. PubMed ID: 21666581
[TBL] [Abstract][Full Text] [Related]
11. New emerging drugs in soft tissue sarcoma.
Milano A; Apice G; Ferrari E; Fazioli F; de Rosa V; de Luna AS; Iaffaioli RV; Caponigro F
Crit Rev Oncol Hematol; 2006 Jul; 59(1):74-84. PubMed ID: 16533604
[TBL] [Abstract][Full Text] [Related]
12. Histology-driven chemotherapy of soft-tissue sarcoma.
Eriksson M
Ann Oncol; 2010 Oct; 21 Suppl 7():vii270-6. PubMed ID: 20943627
[TBL] [Abstract][Full Text] [Related]
13. [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
Qiu MZ; Xu F; Wang SS; Luo HY; Wang F; Li FH; Sun XF; Xu GC; Lin TY; Huang HQ; Jiang WQ; Guan ZZ; Xu RH
Ai Zheng; 2007 Dec; 26(12):1344-9. PubMed ID: 18076798
[TBL] [Abstract][Full Text] [Related]
14. How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers.
Van Tine BA; Trent JC
Curr Med Res Opin; 2019 Apr; 35(4):623-629. PubMed ID: 30652922
[TBL] [Abstract][Full Text] [Related]
15. New developments in targeted therapy for soft tissue sarcoma.
Ganjoo KN
Curr Oncol Rep; 2010 Jul; 12(4):261-5. PubMed ID: 20464642
[TBL] [Abstract][Full Text] [Related]
16. Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma - An analysis of the EORTC 62012 study of the EORTC STBSG.
Grünwald V; Litière S; Young R; Messiou C; Lia M; Wardelmann E; van der Graaf W; Gronchi A; Judson I;
Eur J Cancer; 2016 Sep; 64():44-51. PubMed ID: 27323349
[TBL] [Abstract][Full Text] [Related]
17. Appraising the current role of chemotherapy for the treatment of sarcoma.
D'Adamo DR
Semin Oncol; 2011 Oct; 38 Suppl 3():S19-29. PubMed ID: 22055968
[TBL] [Abstract][Full Text] [Related]
18. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
Italiano A; Toulmonde M; Bui-Nguyen B
Bull Cancer; 2010 Jun; 97(6):679-86. PubMed ID: 20483708
[TBL] [Abstract][Full Text] [Related]
20. Role of chemotherapy in patients with soft tissue sarcomas.
Maki RG
Expert Rev Anticancer Ther; 2004 Apr; 4(2):229-36. PubMed ID: 15056053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
